FDA lists drugs with potential safety issues
A list of drugs currently being evaluated for potential safety issues by the US Food and Drug Administration (FDA) has been posted on its website.
Archives for September 8, 2008
Abraxis and ProMetic target US biopharma market
Abraxis has licensed rights to use ProMetic’s protein technology in the development of four new biopharmaceuticals that it hopes will generate around $600m (€422.5m) in US sales.
Contract manufacturing: News in brief
in-PharmaTechnologist.com’s latest round up of developments in contract manufacturing includes Therapure’s launch and facility expansions by Hollister-Stier, West and Dow.
FDA publishes final rule on cGMP amendments
The US Food and Drug Administration (FDA) has published its latest amendments to current good manufacturing practice (cGMP) regulations.
Phase Forward buys Clarix for $40m
eClinical specialist Phase Forward has added to its portfolio by purchasing interactive-response technology company Clarix for $40m in cash in a move aimed at toppling ClinPhone from its leading position in the sector.
MDS struggles as Pharma Services' revenue drops
Beleaguered life science tools and services company MDS Inc, has recorded disappointing third quarter results, with revenues from its Analytical Technologies and MDS Pharma Services divisions missing forecasts.
Alembic seeks to mix it with US and European players
Indian pharmaceutical firm Alembic is seeking to expand its presence in the lucrative US and European drug markets through an expanded partnering programme.